Other Secondary Peritoneal Surface Malignancies

Patients with peritoneal metastasis (PM) are typically considered as having a terminal and incurable disease [1–3]. Since the late 1990s, a novel therapeutic approach, has emerged combining cytoreductive surgery (CRS) performed to treat all visible disease, plus hyperthermic intraperitoneal chemotherapy (HIPEC) used to treat microscopic residual disease [4, 5]. This treatment radically changed the therapeutic approach to patients with peritoneal surface malignancies and is regarded as the standard of care for pseudomyxoma peritonei from appendiceal cancer and peritoneal mesotheliomas [6, 7]. It also provides improved survival rates for treating PM from ovarian [8–10], gastric [11, 12], and colorectal cancers [13–15].